<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24280898</PMID><DateCompleted><Year>2015</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>3</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>How to understand the efficacy measurements for enterovirus type 71 vaccine?</ArticleTitle><Pagination><StartPage>623</StartPage><EndPage>627</EndPage><MedlinePgn>623-7</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">27253</ELocationID><Abstract><AbstractText>The choice of endpoint was most important for an efficacy vaccine trial. The objective of this paper is to gear toward answering questions about the rationality and scientificity of the primary endpoints choosing, case capturing and diagnosis strategy in our recently reported EV71 vaccine efficacy phase 3 trial. In order to obtain both high sensitivity and specificity in the case detecting, EV71-associated disease had been chosen as primary endpoint, a broad spectrum of clinical symptoms was surveyed, both the real-time RT-PCR and virus isolation were combined for the laboratory diagnosis, and serial specimens since disease onset were collected for assays. Though, the EV71 vaccine efficacy was well measured in the phase 3 trial, several potential factors could also have influences on the cases confirming. More evidence of EV71 vaccine efficacy will be demanded in post-marketing studies in the future.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jing-Xin</ForeName><Initials>JX</Initials><AffiliationInfo><Affiliation>College of Pharmacy; Third Military Medical University &amp; National Engineering Research Center for Immunological Products; Chongqing, PR China; Jiangsu Provincial Center for Disease Control and Prevention; Nanjing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Fan-Yue</ForeName><Initials>FY</Initials><AffiliationInfo><Affiliation>Jiangsu Provincial Center for Disease Control and Prevention; Nanjing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zheng-Lun</ForeName><Initials>ZL</Initials><AffiliationInfo><Affiliation>National Institute for Food and Drug Control; Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qun-Ying</ForeName><Initials>QY</Initials><AffiliationInfo><Affiliation>National Institute for Food and Drug Control; Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Feng-Cai</ForeName><Initials>FC</Initials><AffiliationInfo><Affiliation>Jiangsu Provincial Center for Disease Control and Prevention; Nanjing, PR China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>11</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017326" MajorTopicYN="N">Clinical Trials, Phase III as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023381" MajorTopicYN="Y">Endpoint Determination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">efficacy</Keyword><Keyword MajorTopicYN="N">enterovirus type 71</Keyword><Keyword MajorTopicYN="N">foot and mouth disease</Keyword><Keyword MajorTopicYN="N">hand</Keyword><Keyword MajorTopicYN="N">sensitivity</Keyword><Keyword MajorTopicYN="N">specificity</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24280898</ArticleId><ArticleId IdType="pmc">PMC4130280</ArticleId><ArticleId IdType="doi">10.4161/hv.27253</ArticleId><ArticleId IdType="pii">27253</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev. 2002;26:91&#x2013;107. doi: 10.1111/j.1574-6976.2002.tb00601.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-6976.2002.tb00601.x</ArticleId><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. A Guide to clinical management and public health response for hand, foot and mouth disease (HFMD). 2011 [cited 2012 September 28]; Available from: http://www.wpro.who.int/publications/docs/GuidancefortheclinicalmanagementofHFMD.pdf</Citation></Reference><Reference><Citation>Fujimoto T, Chikahira M, Yoshida S, Ebira H, Hasegawa A, Totsuka A, Nishio O. Outbreak of central nervous system disease associated with hand, foot, and mouth disease in Japan during the summer of 2000: detection and molecular epidemiology of enterovirus 71. Microbiol Immunol. 2002;46:621&#x2013;7. doi: 10.1111/j.1348-0421.2002.tb02743.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1348-0421.2002.tb02743.x</ArticleId><ArticleId IdType="pubmed">12437029</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang FL, Chen CH, Huang SK, Chen PY. An outbreak of enterovirus 71 in a nursery. Scand J Infect Dis. 2010;42:609&#x2013;12. doi: 10.3109/00365541003754444.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365541003754444</ArticleId><ArticleId IdType="pubmed">20429712</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C-C, Tseng H-W, Wang S-M, Wang J-R, Su I-J. An outbreak of enterovirus 71 infection in Taiwan, 1998: epidemiologic and clinical manifestations. J Clin Virol. 2000;17:23&#x2013;30. doi: 10.1016/S1386-6532(00)00068-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1386-6532(00)00068-8</ArticleId><ArticleId IdType="pubmed">10814935</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M. Enterovirus 71: the virus, its infections and outbreaks. J Microbiol Immunol Infect. 2000;33:205&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">11269363</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng KF, Chen LL, Huang PN, Shih SR. Neural pathogenesis of enterovirus 71 infection. Microbes Infect. 2010;12:505&#x2013;10. doi: 10.1016/j.micinf.2010.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2010.03.006</ArticleId><ArticleId IdType="pubmed">20348010</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng FY, Li JX, Li XL, Chu K, Zhang YT, Ji H, Li L, Liang ZL, Zhu FC. Tolerability and immunogenicity of an inactivated enterovirus 71 vaccine in Chinese healthy adults and children: an open label, phase 1 clinical trial. Hum Vaccin Immunother. 2012;8:668&#x2013;74. doi: 10.4161/hv.19521.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.19521</ArticleId><ArticleId IdType="pubmed">22634437</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Liang ZL, Li XL, Ge HM, Meng FY, Mao QY, Zhang YT, Hu YM, Zhang ZY, Li JX, et al. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet. 2013;381:1037&#x2013;45. doi: 10.1016/S0140-6736(12)61764-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)61764-4</ArticleId><ArticleId IdType="pubmed">23352749</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, Wen SQ, Liu Y, Yin WD, Li RC, Wang JZ. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine. 2012;30:3295&#x2013;303. doi: 10.1016/j.vaccine.2012.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.03.010</ArticleId><ArticleId IdType="pubmed">22426327</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou AH, Liu CC, Chang CP, Guo MS, Hsieh SY, Yang WH, Chao HJ, Wu CL, Huang JL, Lee MS, et al. Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates. PLoS One. 2012;7:e34834. doi: 10.1371/journal.pone.0034834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0034834</ArticleId><ArticleId IdType="pmc">PMC3328501</ArticleId><ArticleId IdType="pubmed">22529942</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang ML, Ho MS, Lee MS. Enterovirus 71 vaccine: when will it be available? J Formos Med Assoc. 2011;110:425&#x2013;7. doi: 10.1016/S0929-6646(11)60063-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0929-6646(11)60063-6</ArticleId><ArticleId IdType="pubmed">21742245</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang ZL, Mao QY, Wang YP, Zhu FC, Li JX, Yao X, Gao F, Wu X, Xu M, Wang J. Progress on the research and development of inactivated EV71 whole-virus vaccines. Hum Vaccin Immunother. 2013;9:1701&#x2013;5. doi: 10.4161/hv.24949.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.24949</ArticleId><ArticleId IdType="pmc">PMC3906269</ArticleId><ArticleId IdType="pubmed">23744508</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang YT, Yao X, Chu K, Chen QH, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024&#x2013;32. doi: 10.1016/S0140-6736(13)61049-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Lachenbruch PA. Sensitivity, specificity, and vaccine efficacy. Control Clin Trials. 1998;19:569&#x2013;74. doi: 10.1016/S0197-2456(98)00042-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-2456(98)00042-7</ArticleId><ArticleId IdType="pubmed">9875836</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow SCL, J.P. Efficacy Trials Design and Analysis of Clinical Trials: Concepts and Methodologies. Second Edition ed: John Wiley &amp; Sons, Inc.; 2004.</Citation></Reference><Reference><Citation>Chang LY. Enterovirus 71 in Taiwan. Pediatr Neonatol. 2008;49:103&#x2013;12. doi: 10.1016/S1875-9572(08)60023-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1875-9572(08)60023-6</ArticleId><ArticleId IdType="pubmed">19054914</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Tseng FC, Wang JR, Chi CY, Chong P, Su IJ. Challenges to licensure of enterovirus 71 vaccines. PLoS Negl Trop Dis. 2012;6:e1737. doi: 10.1371/journal.pntd.0001737.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0001737</ArticleId><ArticleId IdType="pmc">PMC3429393</ArticleId><ArticleId IdType="pubmed">22953003</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Tsao KC, Hsia SH, Shih SR, Huang CG, Chan WK, Hsu KH, Fang TY, Huang YC, Lin TY. Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan. JAMA. 2004;291:222&#x2013;7. doi: 10.1001/jama.291.2.222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.291.2.222</ArticleId><ArticleId IdType="pubmed">14722149</ArticleId></ArticleIdList></Reference><Reference><Citation>Simondon F, Khodja H. Capture-recapture method for estimating misclassification errors: application to the measurement of vaccine efficacy in randomized controlled trials. Int J Epidemiol. 1999;28:113&#x2013;6. doi: 10.1093/ije/28.1.113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/28.1.113</ArticleId><ArticleId IdType="pubmed">10195674</ArticleId></ArticleIdList></Reference><Reference><Citation>Orenstein WA, Bernier RH, Hinman AR. Assessing vaccine efficacy in the field. Further observations. Epidemiol Rev. 1988;10:212&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">3066628</ArticleId></ArticleIdList></Reference><Reference><Citation>Merovitz L, Demers AM, Newby D, McDonald J. Enterovirus 71 infections at a Canadian center. Pediatr Infect Dis J. 2000;19:755&#x2013;7. doi: 10.1097/00006454-200008000-00017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006454-200008000-00017</ArticleId><ArticleId IdType="pubmed">10959747</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Liang ZL, Meng FY, Zeng Y, Mao QY, Chu K, Song XF, Yao X, Li JX, Ji H, et al. Retrospective study of the incidence of HFMD and seroepidemiology of antibodies against EV71 and CoxA16 in prenatal women and their infants. PLoS One. 2012;7:e37206. doi: 10.1371/journal.pone.0037206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0037206</ArticleId><ArticleId IdType="pmc">PMC3360679</ArticleId><ArticleId IdType="pubmed">22662137</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Lin TY, Huang YC, Tsao KC, Shih SR, Kuo ML, Ning HC, Chung PW, Kang CM. Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr Infect Dis J. 1999;18:1092&#x2013;6. doi: 10.1097/00006454-199912000-00013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006454-199912000-00013</ArticleId><ArticleId IdType="pubmed">10608631</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim KA, Benyesh-Melnick M. Typing of viruses by combinations of antiserum pools. Application to typing of enteroviruses (Coxsackie and ECHO) J Immunol. 1960;84:309&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">14416964</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung PW, Huang YC, Chang LY, Lin TY, Ning HC. Duration of enterovirus shedding in stool. J Microbiol Immunol Infect. 2001;34:167&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">11605806</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Chow VT, Phoon MC, Chan KP, Poh CL. Direct detection of enterovirus 71 (EV71) in clinical specimens from a hand, foot, and mouth disease outbreak in Singapore by reverse transcription-PCR with universal enterovirus and EV71-specific primers. J Clin Microbiol. 2002;40:2823&#x2013;7. doi: 10.1128/JCM.40.8.2823-2827.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.40.8.2823-2827.2002</ArticleId><ArticleId IdType="pmc">PMC120643</ArticleId><ArticleId IdType="pubmed">12149336</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BA, Kilpatrick DR, Oberste MS, Pallansch MA. Serotype-specific identification of enterovirus 71 by PCR. J Clin Virol. 2000;16:107&#x2013;12. doi: 10.1016/S1386-6532(00)00065-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1386-6532(00)00065-2</ArticleId><ArticleId IdType="pubmed">10720814</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EL, Chow VT, Kumarasinghe G, Lin RT, Mackay IM, Sloots TP, Poh CL. Specific detection of enterovirus 71 directly from clinical specimens using real-time RT-PCR hybridization probe assay. Mol Cell Probes. 2006;20:135&#x2013;40. doi: 10.1016/j.mcp.2005.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcp.2005.11.003</ArticleId><ArticleId IdType="pubmed">16460910</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EL, Yong LL, Quak SH, Yeo WC, Chow VT, Poh CL. Rapid detection of enterovirus 71 by real-time TaqMan RT-PCR. J Clin Virol. 2008;42:203&#x2013;6. doi: 10.1016/j.jcv.2008.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2008.01.001</ArticleId><ArticleId IdType="pubmed">18304867</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu F, Yan Q, Wang H, Niu J, Li L, Zhu F, He S, Zhang S, Weng Z, Cheng T, et al. Performance of detecting IgM antibodies against enterovirus 71 for early diagnosis. PLoS One. 2010;5:e11388. doi: 10.1371/journal.pone.0011388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0011388</ArticleId><ArticleId IdType="pmc">PMC2894942</ArticleId><ArticleId IdType="pubmed">20613983</ArticleId></ArticleIdList></Reference><Reference><Citation>Han J, Ma XJ, Wan JF, Liu YH, Han YL, Chen C, Tian C, Gao C, Wang M, Dong XP. Long persistence of EV71 specific nucleotides in respiratory and feces samples of the patients with Hand-Foot-Mouth Disease after recovery. BMC Infect Dis. 2010;10:178. doi: 10.1186/1471-2334-10-178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-10-178</ArticleId><ArticleId IdType="pmc">PMC2895604</ArticleId><ArticleId IdType="pubmed">20565813</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Lin C, Qu M, Li X, Gao Z, Zhang X, Liu Y, Huang Y, Wang X, Jia L, et al. Excretion of enterovirus 71 in persons infected with hand, foot and mouth disease. Virol J. 2013;10:31. doi: 10.1186/1743-422X-10-31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-10-31</ArticleId><ArticleId IdType="pmc">PMC3560202</ArticleId><ArticleId IdType="pubmed">23343115</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10:778&#x2013;90. doi: 10.1016/S1473-3099(10)70194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan X, Huang X, Zhu S, Chen H, Yu Q, Wang H, Huo X, Zhou J, Wu Y, Yan D, et al. The persistent circulation of enterovirus 71 in People&#x2019;s Republic of China: causing emerging nationwide epidemics since 2008. PLoS One. 2011;6:e25662. doi: 10.1371/journal.pone.0025662.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0025662</ArticleId><ArticleId IdType="pmc">PMC3181342</ArticleId><ArticleId IdType="pubmed">21980521</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TY, Chang LY, Hsia SH, Huang YC, Chiu CH, Hsueh C, Shih SR, Liu CC, Wu MH. The 1998 enterovirus 71 outbreak in Taiwan: pathogenesis and management. Clin Infect Dis. 2002;34(Suppl 2):S52&#x2013;7. doi: 10.1086/338819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/338819</ArticleId><ArticleId IdType="pubmed">11938497</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L-Y, Lin T-Y, Hsu K-H, Huang Y-C, Lin K-L, Hsueh C, Shih SR, Ning HC, Hwang MS, Wang HS, et al. Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet. 1999;354:1682&#x2013;6. doi: 10.1016/S0140-6736(99)04434-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(99)04434-7</ArticleId><ArticleId IdType="pubmed">10568570</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul Y. Herd immunity and herd protection. Vaccine. 2004;22:301&#x2013;2. doi: 10.1016/j.vaccine.2003.07.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2003.07.016</ArticleId><ArticleId IdType="pubmed">14670308</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennett ML, Birch CJ, Lewis FA, Yung AP, Locarnini SA, Gust ID. Enterovirus type 71 infection in Melbourne. Bull World Health Organ. 1974;51:609&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2366271</ArticleId><ArticleId IdType="pubmed">4377551</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford NW, Graham SM. EV71 vaccine: protection from a previously neglected disease. Lancet. 2013;381:1968&#x2013;70. doi: 10.1016/S0140-6736(13)61124-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61124-1</ArticleId><ArticleId IdType="pubmed">23726163</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>